CD274 and hepatocellular carcinoma: What is more, according to the results of IMbrave150, a phase 3 clinical trial, the FDA approved the combination of atezolizumab, selectively targeting PD-L1, and bevacizumab, a VEGF-A-targeting monoclonal antibody, for first-line treatment in patients with unresectable or metastatic HCC [13].